Bayer's Offensive Pivot: From Legal Defendant to Patent Plaintiff Ahead of Tuesday's Numbers

Bayer pivots from glyphosate litigation to patent claims and new drug launches, driving shares up 78% in a year.

The transformation at Bayer is no longer a matter of incremental progress — it's a repositioning that has fundamentally changed how the company approaches its future. The clearest signal came not from the balance sheet, but from the courtroom: Bayer is now the one filing lawsuits, asserting patent claims over mRNA optimization technologies originally developed at Monsanto against vaccine heavyweights Pfizer and Moderna.

That role reversal captures the broader shift underway at the German conglomerate. For years, the company's narrative was dominated by glyphosate litigation and the costly aftermath of the Monsanto acquisition. Now, management is actively seeking to monetize that deal beyond crop science, while simultaneously pushing into new markets and product categories.

The Numbers Behind the Momentum

The market has taken notice. Bayer shares closed Friday at €48.49, capping a week that saw gains of 5.48 percent. The stock has climbed 31.02 percent since the start of the year, and over the trailing twelve months, the advance stands at an even more striking 78.24 percent. The company's market capitalization now sits at €47.59 billion.

Chart technicians point to additional confirmation: the stock trades 23.69 percent above its 200-day moving average, suggesting a firmly established medium-term uptrend. The relative strength index reads 59.5, which, despite the recent run-up, signals the stock hasn't become overbought just yet.

Analyst sentiment mirrors that optimism. Of eight experts surveyed, six rate the stock a buy, with two recommending hold. The average price target comes in at €54.44 — a level that would push the shares past their 52-week high of €53.86, reached in early July. The stock currently sits 9.97 percent below that peak, and the six-month rating trend points decisively upward.

Beyond Glyphosate: A Multi-Pronged Strategy

The legal offensive against Pfizer and Moderna is just one pillar of a broader expansion. In China, Bayer has submitted a regulatory application for Kerendia, a treatment for non-diabetic chronic kidney disease. The addressable patient pool is substantial: Bayer estimates that up to 15 percent of Chinese adults suffer from some form of CKD, making this a bet on scale rather than a niche play.

The agricultural division is also evolving. The company's new "Pack MD Diag+" product combines herbicides with qPCR-based diagnostic tools deployed directly in the field. It's a strategic shift from selling commodity chemistry toward selling data and efficiency — a margin-defense play in a volatile agricultural market.

These initiatives share a common thread: Bayer is no longer waiting for its legal legacy to fully resolve before acting. The company is pressing forward on multiple fronts while the old liabilities continue to wind down in the background.

The Test That Matters

Tuesday, August 4, will provide the clearest read yet on whether this new posture is backed by operational substance. That's when Bayer releases its half-year results, offering investors their first comprehensive look at whether the turnaround has real traction.

The recent trading pattern suggests some underlying nervousness despite the rally. Last week saw both weaker and firmer trading phases, with a soft start on Friday morning before the stock recovered by midday. Institutional investors appeared to trim positions periodically — a classic profit-taking pattern after a strong run.

The improved legal environment around glyphosate has been a key driver of the positive analyst consensus. With that overhang lifting, attention has shifted to the fundamentals. Should Tuesday's numbers disappoint, the recent profit-taking could accelerate quickly. If they confirm the turnaround, the path back toward — and potentially beyond — the 52-week high looks open.